GSK Licenses Linerixibat to Alfasigma in Deal Worth Up to USD 690 Million
Bengaluru: GSK said on Monday it will receive up to USD 690 million from Italian pharmaceutical company Alfasigma for the worldwide rights to linerixibat, an experimental treatment for severe itching in patients with a rare liver disease.
The drug treats cholestatic pruritus, a relentless internal itch affecting patients with primary biliary cholangitis (PBC), an autoimmune disease where the body's immune system attacks bile ducts in the liver.
Alfasigma will pay GSK $300 million upfront plus another $100 million upon expected U.S. approval by March 24. It will pay $20 million when European and UK regulators approve the drug.
GSK is also eligible for up to $270 million in sales milestones and will earn tiered double-digit royalties on worldwide sales from Alfasigma, which already markets treatments for liver diseases across more than 100 countries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.